Sublingual sufentanil, a new opportunity for the improvement of postoperative pain management in Italy by Sacerdote, P et al.
Abstract. – Despite the availability of na-
tional and international guidelines, adequate
postoperative pain (POP) management is still a
challenge in Italy. One of the potential reasons
for the high incidence of surgical patients com-
plaining moderate to severe pain is the difficult
application of the currently recommended anal-
gesic techniques in clinical practice. In particu-
lar, morphine, the most commonly used sys-
temic opioid in the POP treatment, has some
unfavorable pharmacodynamic and pharmaco-
kinetic characteristics for POP management,
suggesting a potential relevant improvement
by using different opioids.
Many of sufentanil properties make it partic-
ularly suitable for POP control: a high affinity
for the µ opioid receptor, the highest therapeu-
tic index compared to any other opioid used in
clinical practice and the absence of clinically
relevant active metabolites.
The elevated potency, together with the high
lipophilicity of sufentanil, allow the preparation of
a nanotablet, 3 mm of diameter and 0.75 mm of
thickness, containing 15 µg of active drug. The
sublingual route allows a longer time of drug
plasmatic permanence in comparison to IV route,
overcoming the need for continuous dosing.
The patient-controlled system, considered in
the present review, is preprogrammed to deliv-
er one sublingual tablet of sufentanil with a 20-
minute lockout period with a radiofrequency
identification thumb tag allowing only the pa-
tient to activate the on demand button.
Phase II and III studies have assessed the ef-
ficacy of this system in POP management,
showing that it was considered more satisfac-
tory than the IV PCA morphine system by both
patients and nurses.
The introduction of this simple and innovative
system of patient-controlled analgesic adminis-
tration could represent an opportunity for Italy to
update the current practice in POP management.
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Introduction
Inadequate post-operative pain (POP) manage-
ment is still a major burden for most healthcare
systems. About 70% of the 240 million post-sur-
gical patients every year suffer from moderate to
severe pain1. 
Uncontrolled POP may result in significant clini-
cal and psychological changes that may lead to a
number of medical complications, including pneu-
monia, infections, deep vein thrombosis, cardiovas-
cular events, and depression. Pain relief has a key
role in multimodal strategies to improve surgical
outcome, together with preoperative assessment, in-
formation and optimization, reduction of surgical
stress, rapid mobilization, and early oral nutrition2.
In the current practice, the effectiveness of
POP management is mainly evaluated through
the cost of treatment, the length of stay, and the
number of unanticipated readmission; however,
these “here and now” outcomes could not be the
right questions to ask. A good-quality periopera-
tive care should be measured through patient-
centred outcome studies in terms of patients’ sat-
isfaction, quality of recovery, quality of life, and
incidence of long-term morbidities, such as
chronic post-surgical pain (CPSP)3.
International and national guidelines4,5 recom-
mend three analgesic techniques, including intra-
venous (IV) patient-controlled analgesia (PCA),
epidural analgesia (EA), and continuous periph-
eral nerve blocks (CPNB). 
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site-specific local anaesthetic (LA) delivery, bet-
ter analgesia, and prevention of premature anal-
gesic block regression12. However, even with the
introduction of ultrasound, PNBs are associated
with an increased risk of infection and likelihood
of hematoma compared with systemic analge-
sia13. Moreover, CPNBs require additional time
to discuss with the patient, to perform the block,
and to obtain the onset of analgesia14.
The most interesting question is why these
techniques and drugs introduced over the past 20
years for acute pain management have not im-
proved postoperative outcomes. One possible ex-
planation is the gap between a clinically mean-
ingful advantage and the availability of resources
necessary to use these techniques, including the
greater risk of possible complications that require
additional clinical surveillance15. 
Recognizing the barriers to effective POP
management is the first step to achieving optimal
post-operative analgesia16.
In Italy, two surveys have been conducted in
2006 (Post Operative Pain Survey in Italy - POP-
SI)17 and 2012 (POPSI-2)18 on POP management,
including data on commonly used analgesic tech-
niques and protocols, healthcare professionals
(HCPs) education, availability of Acute Pain Ser-
vices (APS), and perceived barriers to clinical im-
provement. Both surveys included about 600 Ital-
ian anaesthesiologists with homogeneous regional
distribution across the Country. Despite the grow-
ing interest in Italy on the topic of “pain”, in par-
ticular after the introduction of Law 38/2010, that
assures the right of citizens to have access to pain
therapy, the most recent survey showed no
progress in the treatment of acute pain, confirm-
ing the suboptimal management, probably related
to organizational, cultural, and economic obsta-
cles18. A recent survey involving about 300 Ital-
ian nurses, who daily play a key role in pain man-
agement and spend more time with patients than
any other HCP, showed a low level of knowledge
in the assessment and management of POP19. Im-
plementation of specific training for all the actors
involved in the perioperative period (anaesthesi-
ologists, nurses, surgeons, physiotherapists, pa-
tients, and relatives) is mandatory. However, ac-
cording to the results of POPSI-2, in the last years
in Italy there was a significant reduction of con-
tinuing medical education in postoperative pain
control, probably related to the lack of interest by
pharmaceutical and medical device companies,
which may support the financial expenses of sci-
entific sessions18.
IV-PCA is nowadays the gold standard of
acute pain control. The patient is directly in-
volved in POP management and the dose of anal-
gesics is tailored on real patient’s need. These el-
ements play a key role in providing better anal-
gesia and superior patient satisfaction than PRN
(pro re nata - as needed) parenteral opioids.
There is no evidence that one opioid via IV-PCA
is better than another, however, on an individual
patient basis, one opioid may be more indicated
than another (i.e. morphine for obese patients
and fentanyl for patients with renal impairment)6.
However, IV-PCA requires systematic informa-
tion of patients and adequate caregivers training,
which may need additional time in the periopera-
tive period. Moreover, IV-PCA pumps are prone
to technical problems, including operator errors
(i.e. programming and drug mistakes, inappropri-
ate prescription and concentration, accidental bo-
lus administration during syringe change, mis-
connections) and patient’s errors (i.e. failure to
understand the device or activation of the pump
by others, such as caregivers or relatives)7.
Regional techniques are used alternatively to
direct drug delivery in proximity to the receptor
or near the target tissue.
EA provides better postoperative analgesia
compared with parenteral opioids, regardless of
analgesic drug, location of catheter placement,
and type and time of pain assessment8. More-
over, EA has been shown to significantly reduce
the incidence of postoperative pulmonary com-
plications (PPCs) and to hasten return to postop-
erative gastrointestinal (GI) function9. However,
EA is limited by the high rate of failure (about
one-third of patients receiving either lumbar or
thoracic epidural analgesia)10, the potential for
neurological damage subsequent to spinal
hematoma (permanent injury 1:24,000 to
1:54,000 treated patients) and the risk of infec-
tions. The increasing use of chronic anticoagu-
lant therapy for cardiovascular diseases, includ-
ing new oral anticoagulants for atrial fibrillation,
significantly limited the use of EA, in favor of al-
ternative regional analgesic techniques, such as
paravertebral blocks for thoracic surgery and
Transversus Abdominus Plane (TAP) block for
abdominal and gynecological surgery.
Finally, in orthopaedic surgery, regardless of
catheter location, CPNBs have been shown to
provide superior analgesia and fewer opioid-in-
duced side effects11. When compared with sin-
gle-shot peripheral nerve blocks, CPNBs present
a number of advantages, including prolonged
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The most upsetting result of these surveys is
that in Italy the most commonly used analgesic
technique is the continuous IV infusion of anal-
gesics through elastomeric pump systems (Figure
1). There is no scientific support for the IV use
of these devices, as neither randomized con-
trolled trials have ever tested their efficacy
against proved analgesic techniques, nor recom-
mendations and guidelines include them among
the suggested analgesic approaches. Further-
more, few papers are available on elastomeric
pumps use for LA continuous infusion (perineur-
al or near the surgical wound). However, 50% of
Italian patients continue to be treated with con-
tinuous infusion of opioids or other analgesics.
Use of elastomeric pumps presents a number of
limitations. They do not guarantee tailored post-
operative analgesia and often their use is accom-
panied by under-dosing of opioids to avoid the
risks of a continuous infusion without any safety
feedback. The main reasons for not using PCA
pumps in Italy resulted the costs that limit the
availability, and the length of training for care-
givers. Lack of economic resources is also the
main reason for the limited number of APS in the
Country. Consequently, most of the used proto-
cols are not universally accepted, but have been
written in the hospital local setting and often are
not completely shared even among anaesthesiol-
ogists of the same unit18.
The introduction of simple and innovative sys-
tems of PCA delivery could represent an oppor-
tunity for Italy to update the current practice in
POP management.
The ideal opioid for patient-controlled
analgesia
Moderate to severe POP is usually controlled
using a multimodal approach, including opioids.
Although it is clear that all opioids share the same
mechanism of actions, the single molecules have
specific pharmacodynamic and pharmacokinetic
characteristics that should drive the choice of the
opioid according to the type of pain that need to
be treated, the most convenient route of adminis-
tration, and the characteristic of each patient20-22. 
The theoretical characteristics for and ideal
opioid for post-operative pain control are:
• a rapid and consistent onset of action support-
ed by a fast equilibration between plasma and
the central nervous system (CNS) with a limit-
ed efflux transporter effect;
• be devoid of active metabolites that may accu-
mulate post-operatively increasing the risk for
prolonged sedation or other adverse effects;
• a limited effect of hepatic or renal dysfunction
on clearance;
• an acceptable tolerability profile.
Morphine has some unfavorable pharmacody-
namics and pharmacokinetic characteristics for
POP treatment, suggesting a relevant improve-
ment by using different opioids; However, it rep-
resents the most commonly used opioid for POP
control in Italy18,22-24. 
Figure 1. Analgesic techniques in 2006 vs.
2012 in Italy.
Clinical Pharmacology of Sufentanil
Sufentanil is a highly lipophilic synthetic
piperidine derivative opioid, synthesized in the
mid-1970s and since then used in anesthesiology
for intravenous, epidural and subarachnoid ad-
ministration25,26.
This molecule has many pharmacodynamic
properties that make it particularly suitable for
post-operative pain control. Sufentanil has a high
affinity for the µ opioid receptor27; it is 300-400
fold more potent than morphine and 5-10 fold
more potent than fentanyl28-30. 
The preclinical pharmacology indicates that
sufentanil has the highest therapeutic index (ratio
between the toxic drug dose and the dose that
gives a therapeutic effect in animal studies) com-
pared to any opioids used in the clinic (Table I)28.
In support to clinical relevance of the high thera-
peutic index a few clinical studies have suggest-
ed a lower incidence of respiratory depression
than fentanyl and morphine (Figure 2)24,30.
Sufentanil, as well as fentanyl, is metabolized
in the liver by CYP3A4 and have no clinically
relevant active metabolites (Table I)31. In con-
trast, morphine glucuronide metabolites (Mor-
phine 3-Glucuronide and Morphine 6-Glu-
curonide) are active, and their accumulation rep-
resents a risk for a prolonged duration of action
and untoward effects. A phase III study, compar-
ing sufentanil sublingual tablet versus IV mor-
phine PCA over a 48-hour dosing period, showed
a significant accumulation of plasma morphine
3-Glucoronide in the morphine group30.
Rate of Equilibration Between the 
plasma and Effector Sites (opioid 
Receptor) in central Nervous System
An important parameter to be considered in the
choice of the optimal opioid for PCA is the equili-
bration half-life between the plasma and the µ-
opioid receptor site in the CNS, known as t½Ke0
22,23.
Obviously, opioids function at CNS receptors,
and the plasma/CNS equilibration half time is a re-
liable parameter for predicting onset of action. The
t½Ke0 is experimentally calculated by evaluating an
objective CNS opioid effect (such as miosis or
EEG) and comparing the kinetic of this effect with
plasma drug concentration, therefore, determining
P. Sacerdote, F. Coluzzi, A. Fanelli
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Figure 2. Oxygen desaturation events in a
phase III study SSTS vs. IV PCA MS30.
Plasma/CNS equilibration 
Opioid Therapeutic index*28 Active metabolites31 half-life (t1/2ke0) min
Fentanyl 277 No (CYP3A4) 6.622,32 
Morphine 71 M3G-M6G 168.022-23, 
Sufentanil 26716 No (CYP3A4) 6.232
Table I. Main pharmacodinamic and pharmacokinetic properties of opioids commonly used for POP treatment.
*Therapeutic index is the ratio of LD50/ED50 in preclinical studies; M3G: Morphine-3-glucuronide; M6G: Morphine-6-glu-
curonide
Sufentanil 15 mcg
Sublingual Sublingual 
Sublingual after repeated 40 repeated
Parameter IV single dose doses doses
AUC0-inf (h.pg/ml) Mean (SD) 273.8 (61.1) 125.5 (47.7) 4216.6 (1225) 75.1 (22.4)
Cmax (pg/ml) Mean (SD) 445.1 (312.0) 35.0 (12.2) 276 (77) 249.6 (72.1)
Tmax (h) Mean (SD) 0.1 (0.0) 0.9 (0.3) 10.9(0.5) 0.4 (0.2)
PT1/2 (h) Mean (SD) 0.2 (0.1) 2.2 (0.9) ND 2.5 (0.6)
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the time needed for equilibration between site of
effect and plasma concentration. For opioids that
are lipophilic such as fentanyl and sufentanil this
equilibration is rapid (Table I)28,31. The presence of
efflux transporters such as Glycoprotein P repre-
sents a limiting factor for a fast equilibration.
Sufentanil is not a substrate for Glycoprotein P,
thus guaranteeing a fast and repetitive onset of ac-
tion33. In contrast morphine and its metabolites are
more hydrophilic, have a limited ability to diffuse
in a lipidic environment (CNS) and are substrate
for efflux transporters33; as a consequence the plas-
ma/CNS equilibration of morphine and its metabo-
lites can take hours at difference with the few min-
utes needed for sufentanil and fentanyl (Table I).
In the IV PCA setting, the delayed equilibration
may be overcome by a possible initial overshoot of
drug administration by patients or by rescue drug
bolus, adding a risk for side effects.
Therefore, based on its therapeutic index, lack
of active metabolites and short t1/2Ke0, sufentanil
has optimal characteristics for postoperative
PCA. The obvious question is why this molecule
is not routinely used for IV PCA. The answer is
that sufentanil when injected IV has a rapid high
Cmax, followed by a short alpha-redistribution
half-life, thus resulting in a rapid onset, as de-
scribed above, but also in a very short duration
of action requiring a high redosing frequency.
This pharmacokinetic problem has been over-
come by administering sufentanil via the sublin-
gual route rather than IV.
pharmacokinetic of Sufentanil Sublingual
Tablet
The elevated potency together with the high
lipophilicity of sufentanil allows the preparation
of nanotablet, 3 mm diameter and 0.75 mm thick,
containing 15 µg of active principle (sufentanil
sublingual tablet 15 µg, SST). The small dimen-
sions of the nanotablet are intended to minimize
taste and salivation, when placed under the
tongue, reducing swallowing of saliva containing
drug and maximizing transmucosal uptake. 
Sublingual absorption of SST was evaluated in
several studies, and results demonstrated the fa-
vorable pharmacokinetics that is obtained cou-
pling sufentanil with the sublingual route of ad-
ministration34,35. 
SST, delivered sublingually as single dose,
demonstrated a media plasma half time (Pt1/2, i.e.
the time from Tmax to time at which plasma
concentration reached half of Cmax after drug
discontinuation) of 2.2 hours, significantly
longer than that measured after IV administration
of 0.2 hours (Table II)34. The sublingual route al-
lows a longer time of drug permanence in plas-
ma, and one of the main concern of using sufen-
tanil for IV PCA, that was the need for too fre-
quent dosing, was therefore overcome.
Sufentanil undergoes a significant first pass
effect by the liver, that causes bioavailability by
os to be low, <10%34. As already reported above,
the high potency of sufentanil can be exploited in
the nanotablet adhesive formulation that reduces
the amount of sufentanil solubilized in the saliva
and inadvertently swallowed; together with sub-
lingual route of administration there is guarantee
for a rather high bioavailability, that in relation
to IV administration is 59%. 
The pharmacokinetic properties of a single-
dose administration of sufentanil 15 µg by IV
route of administration reached a mean Cmax of
445 pg/ml, while the measured Cmax after sub-
Table II. Pharmacokinetic properties of 15 µg of sufentanil administered as IV bolus or as SST in single and repeated-dose34-35.
1416
lingual route of the same dose was 35.0 pg/ml
(Table II)34,35. These data clearly indicate that
sublingual administration avoids the peak plasma
concentrations that can be of concern for safety. 
In the treatment of POP, the patients can self
administer repeated doses of SST with a lockout
period of 20 minutes. The pharmacokinetic para-
meters of repeated dosing of SST, one tablet
every 20 minutes for 40 doses was assessed in
healthy volunteers. As expected both Cmax and
AUC were greater after repeated administration
compared with those after single dose of SST
(Table II)34,35. However, it is important to under-
line that the mean Cmax measured with repeated
sublingual administration of sufentanil tablets at
maximal frequency of dosing (every 20 minutes)
was 249.6 pg/ml, that remained lower than that
achieved after a single IV dose of sufentanil
(445.1 pg/ml). These results suggest a great mar-
gin of tolerability for SST also after repeated
dosing, avoiding rapid high plasma concentra-
tions that may produce undesirable adverse ef-
fects (Figure 3). 
Another important parameter that needs to be
taken into consideration in the patient– con-
trolled self administration paradigm with repeat-
ed sufentanil dosing administration, is the Pt1/2
following the last dose of SST after 40 sequential
doses every 20 minutes compared to a single
dose. It is important that this parameter would re-
main fairly stable allowing a predictable and
consistent offset of the analgesic effect of sufen-
tanil after the last administration, avoiding the
risk of delayed adverse effects. The mean Pt1/2 af-
ter a single dose administration of SST was cal-
culated to be 2.2 hours, that become 2.5 hours af-
ter the last repeated (of 40 sequential doses)
dose, indicating no risk of drug accumulation
(Table II). It has also to be underlined that in this
study34, SST was administered at the maximum
allowed frequency (every 20 minutes), while in
the phase 3 studies, the median interval between
dosing in patients was 80-100 minutes30,35,37. 
In contrast, for fentanyl it has been reported
that a prolonged infusion over 4 hours results in
a relevant increase of its Pt1/2, due to high volume
of distribution and its long elimination half-life
(Pt1/2 = 180 minutes after 4 hours and 290 min-
utes after 8 hour infusion)38. 
Risk of Drug interactions
Sufentanil is metabolized in the liver by the
CYP3A4 enzyme, and as a consequence co-ad-
ministration of drugs that affect CYP3A4 may
alter sufentanil metabolism. Indeed in a phase 1
study, ketoconazole a well known CYP3A4 in-
hibitor was co-administered, and a slightly high-
er but not significantly different sufentanil peak
plasma levels were measured (mean Cmax of 40
pg/ml with sufentanil alone and 46 pg/ml togeth-
er with ketoconazole)35. The clinical relevance of
interactions in the post-operative context is how-
ever questionable, considering the short time of
opioid administration in a well-controlled hospi-
tal environment. Moreover, the patient-controlled
nature of this type of analgesia allows the pa-
tients to adjust for any altered metabolism of
sufentanil.
Use of SST in Renal or Hepatic Impairment
In a phase 3 study30 there were no significant
differences in plasma sufentanil concentrations
measured at 24 or 48 hours between patients with
renal impairment (glomerular filtration rate esti-
P. Sacerdote, F. Coluzzi, A. Fanelli
Figure 3. Sufentanil plasma concentra-
tion after single and repeated SST doses34.
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mate based upon creatinine) and those with nor-
mal renal function. Moreover, no significant dif-
ferences for plasma sufentanil were measured
when comparing those patients with mild to
moderate hepatic impairment (as assessed by as-
partate and alanine aminotransferases and total
bilirubin) and those with normal hepatic func-
tion. Indeed, as reported above, sufentanil does
not possess active metabolites that could eventu-
ally accumulate in renal impairment. 
The efficacy of SST in the Treatment of
acute postoperative pain
SST, the new sublingual formulation of
sufentanil, was object of two phase 2 studies
evaluating different dosages in the management
of POP following elective total knee replace-
ment (TKR) and open abdominal surgery
(OAS)36. In the post-anesthesia care unit pa-
tients were randomized to receive placebo, or
an active treatment with sublingual sufentanil
(5, 10, or 15 μg in the TKR study and 10 or 15
μg in the OAS trial). The study drug was ad-
ministered by an investigator as needed at the
request of the patient with a minimum interval
of 20 minutes. One-Hundred-One and 94 pa-
tients were respectively enrolled and random-
ized in the TKR and the OAS study. The
summed pain intensity difference (SPID) scores
for the 15 μg dose were higher than placebo at
all time points in the TKR study and at all time
points starting from the first 3 hours for the
OAS study. The percentages of patient discon-
tinuation in the studies due to inadequate anal-
gesia were dose related. The average interdos-
ing interval for the patients treated with the 15
μg dosage was 73 to 101 minutes and con-
firmed the hypothesis that the sublingual ad-
ministration of sufentanil can effectively treat
POP without the need of frequent on demand
doses. The prevalence of adverse events (AEs)
was similar among groups, except for a higher
incidence of pruritus in the groups treated with
sufentanil. 
The phase 2 dose-finding studies showed that
the dose of 15 μg of sublingual sufentanil (SST)
was the optimal dosage in terms of efficacy and
safety (Table III and Table IV) and it was the one
tested in the phase 3 program. 
In the phase 3 studies, SST was administered
with a preprogrammed, noninvasive patient-con-
trolled system (sufentanil sublingual tablet sys-
Total knee arthroplasty Open abdominal surgery
Sublingual sufentanil Placebo (n = 24) Sublingual sufentanil Placebo 
(n = 30)
Efficacy 5 µg 10 µg 15 µg 10 µg 15 µg 
parameter (n=24) (n=25) (n=20) (n=29) (n=29)
SPID-12, LS mean (SEM) 3 (6) 1 (6) 13 (6)* -7 (6) 22 (4)** 28 (4)** 3 (3)
TOTPAR-12 17 (2) 13 (2) 19 (3) 12 (2) 23 (2)** 26 (2)** 14 (2)
Discontinuation due to 13 (54) 11 (44) 5 (25)** 16 (67) 7 (24)** 3 (10)** 21 (71)
inadequate analgesia, n (%)
Table III. Main efficacy results of the phase II studies, sublingual sufentanil tablets versus placebo35.
*p<0.05 compared with placebo; **p<0.001 compared with placebo.
Possibly or probably related AEs Open abdominal surgery or total knee arthoplasty (%) 
occurring in ≥5% in any group
5 µg (n=24) 10 µg (n=55) 15 µg (n=49) Placebo (n=54)
Nausea 29 40 37 32
Vomiting 8 11 6 6
Dizziness 13 4 2 2
Pruritus 4 7 12* 0
Table IV. Adverse Events of the phase II studies, sublingual sufentanil tablets versus placebo35.
AE: Adverse event, *p=0.042 vs. placebo.
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tem – SSTS; Zalviso®). The device was prepro-
grammed to deliver one sublingual tablet of
sufentanil with a 20-minute lockout period. A ra-
diofrequency identification thumb tag allows on-
ly the patient to activate the on demand button.
To better understand the results of these studies,
it is important to underline that patients involved
were not treated with a multimodal approach and
the enrollment was not limited by age and body
mass index (BMI).
Two placebo-controlled trials and one active
comparator study were conducted in patients un-
dergoing major abdominal and orthopedic surg-
eries30,37,39. 
The two placebo-controlled studies evaluated
the efficacy and safety of SSTS for the manage-
ment of moderate to severe acute postoperative
pain in patients undergoing major open abdominal
or orthopedic surgery37,39. Patients were random-
ized to receive SSTS 15 μg or an identical system
containing placebo tablets. Patients treated with
the SSTS showed a significantly higher SPID and
total pain relief (TOTPAR) scores compared with
patients in the placebo group. The effectiveness of
sufentanil was confirmed by a greater drop in pain
intensity compared with baseline (PID score) than
in the placebo group. In both the studies patients
in the SSTS group showed an average interdosing
time significantly higher compared with the 20
minutes preprogrammed lockout period. In the
majority of the patients, a single cartridge of 40
nanotablets was enough to provide analgesia for at
least 48 hours39. 
Compared with the patients treated with place-
bo, a higher percentage in the SSTS group re-
ported “success” on the patient global assessment
(PGA) as well as, at the same time points, more
health care professionals reported “success” on
the health care professional global assessment
(HPGA). 
Patients in the SSTS group showed a similar
safety profile in terms of AEs considered poten-
tially related to study drug compared with pa-
tients in the placebo system group. This data is
relevant due to the fact that the population in the
two placebo-controlled studies can be considered
at high risk of AEs. In fact, a significant percent-
age of patients enrolled were older than 65 years
of age or with a BMI ≥30 kg/m2, reflecting the
real-life. 
The active comparator study was conducted
and published by Melson et al30, to evaluate the
efficacy and safety of SSTS compared to the
gold standard IV PCA morphine sulfate (IV PCA
MS). To test the analgesic efficacy of the drugs
involved in the study, as well as the delivery
method, the two groups (SSTS vs IV PCA MS)
were compared in terms of 48 hours patient glob-
al assessment (PGA 48) of method of pain con-
trol. The parameters selected for the IV PCA MS
(bolus of 1 mg with a lockout period of 6 min-
utes) were based on the daily practice of many
hospitals. Moreover, they allowed an equivalent
dose of morphine compared to sufentanil in the
same 20 minute time period (15 μg SST = 3 mg
IV MS based on 300 to 400 potency factor and
60% bioavailability of SST). 
Three hundred fifty-seven patients undergoing
open abdominal or orthopedic major joint
surgery (SSTS [n = 177] and IV PCA MS [n =
180]) were treated and the 79% completed the 48
hours study period. There were no significant
differences between the two groups related to the
proportion of patients who discontinued from the
study due to an AE or inadequate analgesia. The
78.5% of the patients in the SSTS group
achieved “success” on the PGA 48 compared to
the 65.6% in the IV PCA MS group, demonstrat-
ing a statistical superiority. Also, the HPGA was
statistically in favor of SSTS at all time points.
The two groups did not present significant differ-
ences in terms of SPID and TOTPAR scores,
even if patients treated with sublingual sufentanil
showed a faster onset of pain reduction with a
significantly greater PID at 1, 2, and 4 hours
(Figure 4). The faster onset of the analgesic ef-
fect of SSTS compared with IV PCA MS was
confirmed by the time required to achieve a
mean PID of 1.3 (1.3 hours vs. 7 hours) which
has been demonstrated clinically significant in
the treatment of acute pain40.
P. Sacerdote, F. Coluzzi, A. Fanelli
Adverse Event occurring SSTS % IV PCA MS (%)
in ≥5% in any group (n = 177) (n = 180)
Nausea 42.9 40.0
Vomiting 13.0 11.1
Constipation 11.3 8.3
Oxygen saturation decreased 9.6 9.4
Headache 7.9 6.7
Hypotension 6.2 11.1
Dizziness 5.6 3.3
Pruritus 4.0 7.8
Table V. Adverse events in the phase III study comparing
SSTS vs. IV PCA MS (AE > 5% in either treatment group)30.
IV PCA MS, Intravenous patient-controlled analgesia mor-
phine sulfate, SSTS, sufentanil sublingual tablet system.
The mean interdosing interval during the study
period was 81 minutes and 47 minutes, in the
SSTS and IV PCA MS groups respectively.
There were no significant differences for any
adverse event between treatment groups (Table
V). Nevertheless, in a high-risk population (for
age (52.4% ≥ 65 years) and BMI (42.9% ≥ 30) a
lower percentage of patients in the SSTS group
compared with IV PCA MS experienced oxygen
desaturation episodes (< 95% recorded on pulse
oximetry) (Figure 2). This difference between
the two groups can be explained by the fact that
morphine has a lower therapeutic index and a de-
layed effector site penetration compared with
sufentanil. Moreover, the morphine active
metabolite morphine-6-glucuronide (M6G) could
increase the risk of oxygen desaturation in partic-
ular in patients with renal impairment.
Based on the easy-of-care (EOC) question-
naire completed by patients and nurses the SSTS
was considered easier to use compared with the
IV PCA system and more satisfactory by both,
patients and nurses (Table VI).
Conclusions
Even nowadays, the treatment of acute postop-
erative pain remains a challenge. Despite the
availability of national and international guide-
lines, a significant percentage of patients still ex-
periences moderate to severe pain after surgery16.
These guidelines recommend continuous regional
analgesic techniques (epidural or peripheral nerve
blocks) or the systemic administration of opioids
trough a patient-controlled device as therapies of
choice after scheduled surgeries characterized by
moderate to severe pain4,5. One of the possible
reasons that can justify the high incidence of un-
controlled pain in the postoperative period is the
poor adherence to these guidelines17,18. In fact, in
Italy the most commonly used pain treatment in
the postoperative context is a continuous infusion
of morphine through an elastomeric pump. Even
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EOC parameter, mean (SD) Orthopedic and open abdominal surgeries
SSTS IV PCA MS p-value
Patient EOC
n 177 180
EOC total, mean (SD) 4.5 (0.5) 4.1 (0.7) <0.001
Confidence with device 4.7 (0.6) 4.5 (0.8) 0.015
Comfort with device 4.5 (0.7) 4.3 (0.7) 0.041
Ease of movement 4.7 (0.7) 3.9 (1.4) <0.001
Dosing confidence 4.7 (0.7) 4.5 (0.9) 0.003
Pain control 3.6 (1.3) 3.2 (1.4) 0.004
Knowledge/understanding 4.5 (0.9) 4.1 (1.1) <0.001
Overall satisfaction 4.2 (1.0) 3.8 (1.0) 0.004
Nurse EOC
n 44 43
EOC total, mean (SD) 4.3 (0.6) 3.8 (0.8) 0.017
Time-consuming 0.9 (0.7) 1.2 (0.9) 0.076
Bothersome 0.5 (0.6) 1.1 (0.9) 0.006
Overall satisfaction 3.9 (0.7) 3.4 (0.6) <0.001
Table VI. EOC questionnaire in the phase III study comparing SSTS vs. IV PCA MS35.
AE: Adverse event, *p=0.042 vs. placebo.
Figure 4. PID over the first hours of treatment in the phase
III study comparing SSTS vs. IV PCA MS30.
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where the electronic PCA devices are available,
they are not used systematically probably due to
some limitations of the currently available IV
PCA devices. These limits include for instance
the requirement of an IV line with a potential in-
creased risk of infection and analgesic gaps due
to IV catheter infiltration or IV tubing obstruc-
tion. Moreover, the possibility of program modi-
fications of the electronic pump can lead to med-
ical and nurse errors with an increased risk of un-
der and over-treatment41 and significant costs for
each error event42. 
The sufentanil sublingual tablet system is in-
stead preprogrammed and it does not require an
IV line. The non programmable nature of SSTS
in the fragile patient may be perceived as a limi-
tation but if it is important to underline that data
from the phase 3 program of SSTS showed an ef-
fective treatment of pain with a significantly
higher mean interdosing interval compared with
the preprogrammed lockout, giving the possibili-
ty to achieve the therapeutic dose through a wide
range of on-demand administrations until the at-
tainment of the 20 minutes interdosing interval.
In this view, the choice not to limit the enroll-
ment of patients in the phase 3 program by age
and BMI, avoiding the selection of a population
far from real practice, makes the safety profile
showed by SSTS clinically significant. More da-
ta related to the effectiveness of the SSTS in the
highly opioid-tolerant patients has to be collect-
ed, due to the fact that this small group of pa-
tients should probably benefit of a tailored ap-
proach to postoperative pain.
The selection of an opioid with a close associ-
ation between patient dosing and peak of CNS
effect is fundamental to avoid dose accumulation
and to reduce the occurrence of side effects34.
Morphine presents a slow-equilibrating time and
sometimes requires multiple doses to optimize
the analgesia in the initial period of treatment,
potentially followed by a delayed opioid balance
with CNS μ receptors, therefore producing AEs.
The dose-stacking phenomenon is exacerbated
by the fact that the active metabolite of mor-
phine, M6G, has an even longer equilibration
time with the CNS compared to morphine43. On
the contrary, sufentanil presents a faster uptake
from the plasma to the μ-opioid effector site in
the CNS with a t1/2Ke0 of 6.2 minutes.
In conclusion, a peak of plasma concentration of
18 min after repeated sublingual administration
showed by Willsie et al, matching with the lockout
period of 20 minutes preprogrammed for the SSTS
device, a rapid equilibration time with CNS and
the lack of active metabolites make sufentanil the
ideal opioid for PCA administration. Moreover, to
guarantee adherence to the guidelines, the nano-
tablets of sublingual sufentanil can be delivered
only through a specific preprogrammed patient-
controlled device, that potentially decreases the
risk of and-over-treatment related to drug and/or
medical errors. The SSTS was also favorably rated
by HCP, including nurses.
A non-invasive and easy to use patient-con-
trolled device with an effective and safe opioid
like the SSTS system may hopefully represent an
alternative to the too frequently used elastomeric
pumps, improving the adherence of the Italian
postoperative pain management to the currently
available guidelines.
Further studies are needed to better understand
the clinical role of SSTS within a multimodal ap-
proach to postoperative pain management.
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